Met Life Investment Management, LLC Cullinan Oncology, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 32,058 shares of CGEM stock, worth $307,436. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,058
Previous 29,841
7.43%
Holding current value
$307,436
Previous $499,000
21.84%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding CGEM
# of Institutions
153Shares Held
68MCall Options Held
612KPut Options Held
118K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$73.3 Million19.97% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$55.1 Million3.06% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$34 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$32.7 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.28MShares$31.5 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $437M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...